Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

Part of paid clinical trials in New Haven, Connecticut.

Sponsor: Yale University
Study ID: NCT00785798
Phase: PHASE1/PHASE2
Status: Terminated

Conditions

Refractory Lymphomas
Relapsed Lymphomas

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Vorinostat — DRUG
200mg to 400 mg twice daily on days 1-7
Pegylated Liposomal Doxorubicin (PLD), Doxil — DRUG
IV 30mg/m2 on day 3 of a 21-day cycle

Study Details

The study will be a dose-finding, phase I study of the combination of vorinostat and PLD in patients with advanced lymphoma refractory to at least one prior systemic therapy.

Key Dates

Start date: Jan 31, 2009
Status verified: Mar 2022
Primary completion: Sep 30, 2011
Completion: Sep 30, 2011

Study Design

Enrollment: 17 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: vorinostat doxil
Escalating doses of vorinostat 200mg to 400mg twice daily on days 1-7, and fixed-dose IV PLD 30mg/m2 on day 3 of a 21-day cycle

Primary Outcome Measure

Overall Response Rate [ Time Frame: end of study (up to 2 years) ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Yale University School of Medicine	New Haven	Connecticut	06520	-

Find similar trials in New Haven, CT

By research site

Yale University School of Medicine· New Haven, CT